uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
5.82
+0.12 (2.11%)
Nov 21, 2024, 1:18 PM EST - Market open
uniQure Employees
uniQure had 480 employees as of December 31, 2023. The number of employees decreased by 21 or -4.19% compared to the previous year.
Employees
480
Change (1Y)
-21
Growth (1Y)
-4.19%
Revenue / Employee
$59,556
Profits / Employee
-$498,960
Market Cap
280.27M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
OraSure Technologies | 638 |
Sage Therapeutics | 487 |
Vanda Pharmaceuticals | 203 |
Voyager Therapeutics | 162 |
C4 Therapeutics | 145 |
Kodiak Sciences | 111 |
ClearPoint Neuro | 107 |
Atai Life Sciences | 83 |
QURE News
- 5 hours ago - uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy - GlobeNewsWire
- 16 days ago - uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 5 weeks ago - uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS - GlobeNewsWire
- 2 months ago - uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire
- 3 months ago - uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire
- 3 months ago - uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity - Seeking Alpha
- 4 months ago - uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 4 months ago - uniQure Announces Closing of Sale of Manufacturing Facility to Genezen - GlobeNewsWire